Overview
Jonathan P. Piccini, MD, MHS, FACC, FAHA, FHRS is a clinical cardiac electrophysiologist and Professor of Medicine and Population Health at Duke University Hospital and the Duke Clinical Research Institute. He is the Director of the Cardiac Electrophysiology section at the Duke Heart Center. His focus is on the care of patients with atrial fibrillation and complex arrhythmias, with particular emphasis on catheter ablation, pacing, and lead extraction. His research interests include the development and evaluation of innovative cardiovascular interventions for the treatment of heart rhythm disorders. He serves on the Board of Trustees of the Heart Rhythm Society, is an Associate Editor at JACC: Clinical Electrophysiology, and is an elected member of the American Society for Clinical Investigation. Dr. Piccini has more than 600 publications in the field of heart rhythm medicine and has been the recipient of several teaching and mentorship awards.
Current Duke Appointments & Affiliations
Recent Scholarly Works
Predictors of ischemic stroke and major bleeding among patients with atrial fibrillation in clinical practice.
Journal article Am Heart J · October 2026 BACKGROUND: Numerous risk scores exist to quantify the risk of ischemic stroke risk in patients with atrial fibrillation or flutter (AF/AFL). However, how these tools perform in cohorts or those already on oral anticoagulation (OAC) therapy is unclear. MET ... Full text Link to item CitePreclinical evaluation of a novel 8-spline pulsed field ablation system.
Journal article Heart Rhythm · July 2026 BACKGROUND: Pulsed field ablation (PFA) technologies offer the potential for improved procedural efficacy and safety. Circumferential pulmonary vein (PV) ablation approaches are attractive compared with point-by-point, simplifying workflow. OBJECTIVE: We e ... Full text Link to item CiteImpact of atrial fibrillation burden on quality of life and prediction of health care utilization: Primary results from the DEFINE AFib study.
Journal article Heart Rhythm · July 2026 BACKGROUND: Atrial fibrillation (AF) can lead to significant cardiovascular events and health care utilization. Continuous monitoring via insertable cardiac monitors (ICMs) and data analytics have the potential to improve care delivery. OBJECTIVE: The DEFI ... Full text Link to item CiteRecent Grants
A randomized, placebo-controlled, participant-and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2029HORIZON -360 PAF IDE protocol for the Treatment of Paroxysmal Atrial Fibrillation with the Sphere-360¿ Catheter and Affera¿ Mapping and Ablation System
Clinical TrialPrincipal Investigator · Awarded by Medtronic, Inc. · 2026 - 2028Duke Lead Extraction Course
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by Philips Image Guided Therapy Corporation · 2024 - 2027View All Grants